CytoImmune Therapeutics
CytoImmune Therapeutics is a privately held clinical-stage biotechnology company developing off-the-shelf allogeneic CAR-NK cell therapies built on its TRACK-NK and Coalescent platforms for solid tumors and hematologic malignancies, manufactured at its Puerto Rico cGMP facility and licensed from City of Hope.
- Company typePrivate
- Founded2017
- HeadquartersMonrovia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CytoImmune Therapeutics does
CytoImmune Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 by Michael Caligiuri, M.D. and Jianhua Yu, Ph.D., developing off-the-shelf allogeneic CAR-NK (chimeric antigen receptor natural killer) cell therapies for cancer. The company's portfolio is built on two proprietary platforms — TRACK-NK (Tumor-Reactive and Anti-PD-L1 Co-stimulated Killer Cells, with triple cytokine induction and optional anti-PD-L1 combination) and Coalescent (triple-edit NK cells expressing a CAR plus secretory soluble IL-15 and a BiKE bispecific killer engager). Lead clinical assets include CYTO-102 (TRACK-NK for NSCLC), CYTO-201 (FLT3 CAR-NK for AML), CYTO NK-203 (PSCA CAR-NK for pancreatic cancer) and a GPRC5D/BCMA CAR-NK for multiple myeloma.
The company's core technology uses umbilical cord blood-derived NK cells engineered via retroviral transduction — a deliberate choice that avoids the chromosomal abnormality risk of gene-editing approaches used by competitors. Only an estimated 2 of 10 umbilical cords yield NK cells suitable for expansion; a proprietary bioassay selects viable cords, and K562 feeder cells expressing membrane-bound IL-21 and 4-1BB ligand drive 1,500-2,000-fold expansion. From a single cord the company can dose 10-20+ patients without inducing immune cell exhaustion. The product has been engineered to function as off-the-shelf therapy with no HLA matching required, controlled expansion to mitigate cytokine release syndrome and ICANS risk, and cryopreservation with 90% post-thaw viability.
CytoImmune is pre-revenue. Its go-to-market is structured for clinical trials via partnerships with research hospitals (City of Hope is the foundational partner and Phase 1 trial site for CYTO-102) and ultimately for outpatient hospital administration post-approval. The company operates a 37,000 sq ft in-house cGMP manufacturing facility in Toa Baja, Puerto Rico, capable of 4,000 doses/year with Phase II expansion planned to 40,000 doses/year, and benefits from approximately $15M in Puerto Rico tax credits in 2021 projected at ~$20M annually. Expected future revenue is structured as licensing/royalties on commercialization of cell therapy products. Headcount is 51-100 with approximately 40+ in Puerto Rico manufacturing; corporate headquarters is in Duarte, California, with a regional subsidiary in Melbourne, Australia.
CytoImmune Therapeutics firmographics
Firmographics- Name
- CytoImmune Therapeutics
- Legal name
- CytoImmune Therapeutics, Inc.
- Website
- https://cytoimmune.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CytoImmune Therapeutics is a privately held clinical-stage biotechnology company developing off-the-shelf allogeneic CAR-NK cell therapies built on its TRACK-NK and Coalescent platforms for solid tumors and hematologic malignancies, manufactured at its Puerto Rico cGMP facility and licensed from City of Hope.
- Ownership category
- akta.pro rank
CytoImmune Therapeutics industry classification
Industry- Product category
- CAR-NK Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- NK Cell Therapies (HLAAABAD)
- akta.pro secondary industry
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
Keywords
Where CytoImmune Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Monrovia
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
CytoImmune Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Cell Therapy Commercialization: Pre-revenue clinical stage company developing NK cell immunotherapy products for cancer treatment. Revenue expected from commercialization of CAR-NK cell therapies for solid tumors and hematologic malignancies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Estimated manufacturing cost per dose |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CytoImmune Therapeutics product offering
Product offeringCore offering
CytoImmune Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic CAR-NK cell therapies manufactured from umbilical cord blood for solid tumors and hematologic malignancies. Its pipeline candidates include CYTO-102 (NSCLC), CYTO-201 (AML), CYTO NK-203 (pancreatic cancer), and a GPRC5D/BCMA BiKE-secreting CAR-NK for multiple myeloma, all engineered through the proprietary TRACK-NK and Coalescent platforms. The company runs its own 37,000 ft2 cGMP clinical manufacturing facility in Puerto Rico.
Product overview
CytoImmune Therapeutics is a clinical-stage biotechnology company developing a portfolio of engineered NK (natural killer) cell-based cancer therapies. The company's product portfolio centers on two proprietary platforms: TRACK-NK (Tumor-Reactive and Anti-PD-L1 Co-stimulated Killer Cells) and Coalescent. Key products include CYTO-102 (TRACK-NK for NSCLC), CYTO-201 (FLT3 CAR-NK for AML), CYTO NK-203 (PSCA CAR-NK for pancreatic cancer), and GPRC5D BiKE secreting BCMA CAR-NK for multiple myeloma. These off-the-shelf allogeneic therapies are manufactured from umbilical cord blood and engineered to express CARs, secrete IL-15 for sustained activity, and optionally secrete bispecific killer engagers (BiKEs). The company operates its own GMP manufacturing facility in Puerto Rico.
Differentiator
Problem solved
Functional benefit
Products and services
- CYTO-102 (TRACK-NK) Allogeneic CAR-NK cell therapy engineered to secrete high levels of soluble IL-15 and react to PD-L1-positive tumors; developed as monotherapy and in combination with atezolizumab for non-small cell lung cancer (NSCLC).
- CYTO-201 (FLT3 CAR-NK) Allogeneic FLT3-directed CAR-NK cell therapy co-expressing soluble IL-15; developed for acute myeloid leukemia (AML).
- CYTO NK-203 (PSCA CAR-NK) Off-the-shelf allogeneic CAR-NK cell therapy derived from umbilical cord blood expressing a CAR against prostate stem cell antigen (PSCA) with soluble IL-15; developed for pancreatic cancer.
- GPRC5D BiKE Secreting BCMA CAR-NK Allogeneic CAR-NK cell therapy secreting a bispecific killer engager (BiKE) that targets GPRC5D and BCMA, for the treatment of multiple myeloma.
Companies that use CytoImmune Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
CytoImmune Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CytoImmune Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Matica BiotechnologycoreStrategic partnership for viral vector and cell therapy production. Matica Biotechnology partnered with CytoImmune Therapeutics for viral vector manufacturing and cell therapy production to advance CytoImmune's cell therapy programs.
- City of Hope National Medical CentercoreFoundational research and clinical trial partnership. City of Hope licensed patent applications to CytoImmune and conducts clinical trials including Phase 1 trial of CYTO-102 in NSCLC. Collaboration based on technologies developed by founders Michael Caligiuri and Jianhua Yu.
Scale indicators3 records
Recent moves9 records
Expansion highlights5 records
CytoImmune Therapeutics competitors and assessment
Company assessmentDirect peers
- Fate Therapeutics: Fate Therapeutics is a leading iPSC-derived NK and T-cell therapy company pursuing off-the-shelf cell therapies for cancer, representing the most advanced direct competitor in engineered NK space and an analogous manufacturing-and-platform capital-light thesis.
- Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (including NK and T-cell programs) for cancer, overlapping the broader allogeneic engineered NK cell therapy category and competing for similar hematologic malignancy indications.
- Allogene Therapeutics: Allogene is a clinical-stage leader in allogeneic CAR-T cell therapies (with parallel NK interests), sharing the off-the-shelf, "healthy-donor-derived" cell therapy positioning and competing for capital, partnerships, and oncology indications.
- Caribou Biosciences: Caribou develops allogeneic CAR-NK and CAR-T cell therapies using CRISPR-based gene editing for oncology, sharing the allogeneic, off-the-shelf cell therapy positioning and competing for similar hematology and solid tumor indications.
- Nkarta Inc. Nkarta is a clinical-stage biotech developing allogeneic CAR-NK cell therapies for hematologic malignancies and solid tumors, built on a similar cord-blood-derived NK engineering platform and directly competing for the same off-the-shelf CAR-NK opportunity as CytoImmune.
Broad incumbents
- Atara Biotherapeutics: Atara is a more mature allogeneic T-cell therapy company whose allogeneic platform parallels CytoImmune's NK approach; CEO Vidal's CMC background at Atara directly connects the two companies and represents a relevant comparable for commercial-scale allogeneic manufacturing.
- Cellectis (Allogene legacy): Cellectis is a foundational allogeneic CAR-T platform company using gene editing, conceptually adjacent to CytoImmune's allogeneic NK platform and a relevant broad comparable in off-the-shelf engineered cell therapy.
Emerging players
- Shoreline Biosciences: Shoreline Biosciences is an early-stage developer of iPSC-derived NK cell therapies with strategic partnerships, pursuing similar off-the-shelf NK oncology applications as CytoImmune but at an earlier stage.
Others
- Matica Biotechnology: Matica Biotechnology is a viral vector and cell therapy CDMO with a strategic partnership with CytoImmune for production; while not a direct competitor, it is a comparable cell-therapy manufacturing platform relevant to CytoImmune's outsourced capacity strategy.
- City of Hope / COH Ventures (research partner): City of Hope is the academic medical center from which CytoImmune licensed its core NK platform IP and conducts CytoImmune's lead Phase 1 clinical trials, making it both a research/clinical partner and a key ecosystem reference for NK cell therapy development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
CytoImmune Therapeutics social profiles
Digital presenceCytoImmune Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CytoImmune Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
CytoImmune Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
CytoImmune Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CytoImmune Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CytoImmune Therapeutics
What does CytoImmune Therapeutics do?
CytoImmune Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic CAR-NK cell therapies manufactured from umbilical cord blood for solid tumors and hematologic malignancies. Its pipeline candidates include CYTO-102 (NSCLC), CYTO-201 (AML), CYTO NK-203 (pancreatic cancer), and a GPRC5D/BCMA BiKE-secreting CAR-NK for multiple myeloma, all engineered through the proprietary TRACK-NK and Coalescent platforms. The company runs its own 37,000 ft2 cGMP clinical manufacturing facility in Puerto Rico.
Is CytoImmune Therapeutics a public or private company?
CytoImmune Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was CytoImmune Therapeutics founded?
CytoImmune Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is CytoImmune Therapeutics based?
CytoImmune Therapeutics is headquartered in Monrovia, United States, in the North America region.
How does CytoImmune Therapeutics make money?
One revenue line is on record: cell Therapy Commercialization.
Who are CytoImmune Therapeutics's main competitors?
Direct peers on record are Fate Therapeutics, Century Therapeutics, Allogene Therapeutics, Caribou Biosciences and Nkarta Inc.. Broad incumbents are Atara Biotherapeutics and Cellectis (Allogene legacy). Shoreline Biosciences is listed as an emerging player. Others are Matica Biotechnology and City of Hope / COH Ventures (research partner).
Does CytoImmune Therapeutics have an API?
No public API is recorded for CytoImmune Therapeutics.
What industry is CytoImmune Therapeutics in?
CytoImmune Therapeutics's product category is CAR-NK Cell Therapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.